Top Penny Stocks To Watch In May 2025

In This Article:

As May 2025 unfolds, the U.S. stock market is experiencing a mix of optimism and caution, with indices like the S&P 500 and Nasdaq poised for their best monthly performance since 2023 amid ongoing trade discussions and economic data surprises. In this climate, penny stocks—often associated with smaller or newer companies—continue to capture investor interest due to their potential for growth at lower price points. Despite being considered a throwback term, these stocks can offer compelling opportunities when backed by strong financials and robust fundamentals.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Perfect (NYSE:PERF)

$1.83

$186.38M

★★★★★★

WM Technology (NasdaqGS:MAPS)

$1.05

$174.9M

★★★★★★

Puma Biotechnology (NasdaqGS:PBYI)

$3.38

$167.28M

★★★★★★

Flexible Solutions International (NYSEAM:FSI)

$4.31

$55.16M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.84

$98.08M

★★★★★★

Table Trac (OTCPK:TBTC)

$4.77

$21.99M

★★★★★★

BAB (OTCPK:BABB)

$0.848

$6.03M

★★★★★★

Lifetime Brands (NasdaqGS:LCUT)

$3.47

$71.05M

★★★★★☆

New Horizon Aircraft (NasdaqCM:HOVR)

$1.10

$30.73M

★★★★★★

Greenland Technologies Holding (NasdaqCM:GTEC)

$2.02

$34.79M

★★★★★★

Click here to see the full list of 730 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

OraSure Technologies

Simply Wall St Financial Health Rating: ★★★★★★

Overview: OraSure Technologies, Inc. is a company that develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices globally with a market cap of $207.20 million.

Operations: OraSure Technologies generates revenue of $161.63 million from its Diagnostics and Molecular Solutions segment.

Market Cap: $207.2M

OraSure Technologies, with a market cap of US$207.20 million, is navigating the challenges typical for penny stocks. Despite being unprofitable, it has managed to reduce losses over the past five years and maintains a strong balance sheet with short-term assets of US$313.8 million exceeding both short-term and long-term liabilities. Recent developments include a collaboration with Targeted Genomics to expand consumer access to at-home celiac genetic testing and filing shelf registrations potentially raising up to US$315.78 million, which could provide financial flexibility but may also lead to shareholder dilution if executed fully.